The androgenic disease of menopause

If there is no symptom, there is no disease. If there is no disease no curative treatment is necessary.

Is there a disease behind the word of menopause ?

***

Errors in menopause treatment.

Warning
The concept and pathology of "menopausal disease" has never been described before. The reality of this pathological entity is founded:

1. on knowledge of the physiology and hormonal biochemistry of the female cycle, found in the excellent hormonology treatises (see: Baulieu E-E. and Kelly Paul A. Hormones, Hermann publishers, 1990).

2. on clinical experience and detailed biochemical analyzes that began in 1998 in "postmenopausal" women with  characteristic symptoms of "menopausal disease". The initial clinical study was pursued by an appropriate therapeutic attitude when the "menopausal disease" is diagnosed biochemically.

3. on the clinical and biological study of women who have been treated with mesterolone and who have been relieved of their symptoms.

4. each biological study here concerns the biochemical and clinical singularity of each woman.

5. The word "menopause" is limited to the cessation of menstruation. Therefore, "therapeutics of this word" do not relate to a disease an doesn't need a treatment.

7. The terminology "menopause disease" corresponds in linguistics to a terminological use of collocations. The term Androgenic Disease of Menopause is more convenient.

The menopause disease (androgenic disease of menopause).pdf  Octobre 2015.    SEMAL Madrid

G. Debled. The menopause disease (androgenic disease of menopause). Approaches to aging control : 19:17-24,October 2015

CAUSE

The ovaries secrete estradiol, progesterone and testosterone.

The cessation of estradiol and progesterone are linked with the stop of ovulation

 and of menstrual hemorrhages which are physiological changes.

The drastic reduction in the secretion of androgens hormones by the ovaries (at an age where the production of androgens by the suprarenal glands is already decreased) is generally not taken into account and brings about the androgenic disease of menopause.

Blood rates of ovarian hormones in woman before menopause.

 The ovaries secrete estradiol, progesterone and testosterone.

The secretions of these three hormones stop in the ovaries at the time of the menopause.

The secretory and proliferative cycle controlled by estradiol and progesterone intended to fertilize ovules does not exist any more after the “suspension of the menses”. One can logically wonder which reason would justify a systematic replacement of these hormones except the fact of wanting to prolong in time an ovarian cycle become useless in the absence of ovulation?  

The total production of testosterone during a menstrual cycle is more important in quantity compared with the production of estradiol.

Consequently one is in right to ask for why estradiol substitution was proposed in the past by neglecting the production of testosterone?

The sharp fall of front testosterone secretion at the time and after the stop of menses is responsible for most of the disorders caused by the menopause disease.

CONSEQUENCES AND SYMPTOMS

The reduction in androgens’ production causes in woman to different degree:

·         functional  symptoms : hot flashes, irritability, intestinal distension, swollen legs.

·         local consequences :

o   sclerosis of bladder neck (chronic cystitis, incontinence, urgencies)

o   sclerosis of vulva (painful or difficult copulation).

·         general consequences  :

o   lipids’ disorders

o   vascular disorders

o   weakness

o    hyper coagulation

o   venous thrombosis

o   rheumatic problems

o    nervous breakdown

o   cerebral involution

o   Alzheimer’s disease

These consequences are wrongfully allotted to the lack of estradiol and progesterone (a polluted concept) whereas in fact they are the consequences of a lack of male hormones (testosterone for general consequences and dihydrotestosterone for local genital involution).

General Symptoms are the same in man suffering from andropause disease described for the first time by Georges Debled in 1988. See: http://www.man.uk.georgesdebled.org/andropause cause book.htm and http://www.man.uk.georgesdebled.org/andropause uk.htm

Local Symptoms resulting from of masculine genitalia involutions are:

·         chronic cystitis, incontinence, urgencies.  (sclerosis of bladder neck)

·          painful or difficult copulation ( sclerosis of vulva)

and  are consequences of a lack of dihydrotestosterone production (lack of testosterone leads to a decreased production of dihydrotestosterone).

Balanced treatment with male hormones (mesterolone) is indicated in menopause disease as in andropause disease.

This fact is generally ignored so that the administration of estradiol (or estrogens) associated or not with progesterone or progestogens doesn’t constitute the treatment for the menopause disease whose I gave the definition (androgens’ deficiencies).

One can even wonder whether the “traditional” treatments of hormonal replacement therapy (HRT) do not worsen the state of good health. See http://www.whi.org                      

TREATMENT OF IN ANDROGENS’ DEFICIENCIES AND OF MENOPAUSE DISEASE (Dr Georges Debled’s definition) WITH MESTEROLONE

If there is no symptom, there is no disease. If there is no disease no curative treatment is necessary.

Orally administration of mesterolone in amounts between 5 milligrams and 25 milligrams per day constitutes the specific treatment.

Interest for the pharmaceutical industry

 1.       Today Mesterolone is not prescribed for woman and its prescription is even exclusive for male patients.

 2.             The North American Menopause Society (NAMS) defines Androgens as: “a group of hormones that promote the development and maintenance of male secondary sex characteristics and structures. They are produced in smaller quantities in women and are important in the synthesis of estrogen. They also play a role in sexual function, muscle mass and strength, bone density, distribution of fat tissue, energy, and psychological well-being. With women, the major androgens are produced in the ovaries and adrenal glands and include testosterone, androstenedione, and dehydroepiandrosterone (DHEA). Also available as prescription and nonprescription therapies, but not government approved for use in women”.

Mesterolone administration is prohibited for woman by the manufacturers because of risks of virilisation as opposed to what this description shows with physiological doses.

Mesterolone covers all indications for androgens with women

3.   It is here question to industrialize mesterolone at very another end that for which it was intended by manufacturing tablets of 5 and 10 milligrams sectile in two parts what makes it possible to cover a large range of therapeutic amounts.

4.   Mesterolone is a hormone prescribed for man to compensate a lack of production of  androgens. Used for man since 1967 it is henceforth in the public domain. Its manufacturing technique is known. No harmfulness was described to date.

5.   Before menopause woman secretes each day of the cycle 0.2 milligrams of testosterone = 200 micrograms or    200,000 nanograms or 200,000,000 picograms. Mesterolone makes it possible to replace androgens whose production is strongly decreased in woman with menopause disease.

6.   The indications relate to all the therapeutic ones containing mesterolone for woman; that the mesterolone is used alone or in partnership with all the pharmaceutical compositions using estrogens alone or in partnership with progesterone or progestogens ones.

7. Mesterolone prescription is the right way to treat premenopausal problems in addition to compositions using estrogens alone or in partnership with progesterone or progestogens ones. Mesterolone balances the properties of estrogens (prescribed with or without  progestogens)  impairing and excess of actions o their hormonal targets.

8. "Traditional" compounding is not prohibited. However the interest of the industrialization for women is evident. Making also dermal patches and pills with long lasting effects.

Why is mesterolone the treatment for androgen's deficiencies in woman ?

Mesterolone cannot be aromatized in estradiol (contrary to testosterone). Its methyl radical  inserted on Carbon 1 of the testosterone confers this property.

 At physiological doses Mesterolone does not influence the secretion of the pituitary gland so that the secretion of LH is not modified (contrary to testosterone).

•          Mesterolone prescribed in small amounts adds its effects to those of testosterone secreted by the organism.

•          With the prescribed physiological pharmacological amounts doping is impossible and the overdose too. Mesterolone is prescribed orally in amounts varying between 5 milligrams and ten milligrams per day approximately. A substitution amount of 25 milligrams per day can be considered. The secretion of LH by the pituitary gland is not inhibited (contrary to testosterone).

Mesterolone molecular structure has characteristics of dihydrotestosterone (DHT) which is directly effective on the masculine sex organs of women (clitoris, labia majora and bladder neck) and on brain tissue (preventing Alzheimer’s disease) (15).

Mesterolone can be prescribed alone.

To restore balance with the androgens Mesterolone can be associated with certain compositions containing estradiol and of progesterone (or progestogens) in cases or these treatments would justify themselves. Any woman secretes each day 0.2 milligrams of male hormones. This balance is essential to the good performance of the hormonal targets. It is most probably this lack of balance by default of androgens which explains the disasters revealed by the “WOMENS' HEALTH INITIATIVE” in addition to inadequate diagnosis and treatments whith estradiol and progestogens. http://www.whi.org             

Non-existent risks of virilism with mesterolone treatment

The treatment of androgen’s deficiency simply consists in replacing missing secretions of testosterone (and dihydrotestosterone) thanks to mesterolone properties.  In this case the woman finds simply her former physiological state and prevents the disastrous consequences described above. Mesterolone used in small amounts allows that.

 Virilism secondary to an excessive administration of mesterolone is the consequence of a doping which must be avoided in all cases. Virilism doesn’t exist at physiological doses

Androgen's scientific biological deficit - Diagnosis background

About determination of testosterone  and dihydrotestosterone in serum :

• The GC-MS (Gaz Chromatography- Mass Spectrometry) is the most precise method (Taieb and all, 2003) (8)

• Direct RIA studies are significant  (ACS 180 from Bayer Diagnostics) (Davison SL and all. 2005 ) (9)

• Androgen glucuronides, instead of testosterone, are interesting markers of androgenic activity in women (Labrie F. and all.2006) (10).

In the Georges Debled’s study the scientific biological diagnosis of androgen’s deficiencies is made on the total “pool” of androgens (RIA) in men since 40 years and in women since 13 years concluding that the level of androgens’ daily production is a key diagnosis (see below).This method led Georges Debled MD. to the concept of andropause disease (which is different from hypogonadism) which treatment is made with mesterolone (See: www.man.uk.georgesdebled.org/andropause uk.htm)

The 10 years’ study on androgens’ deficiencies in women is founded on RIA analyses made by a reference laboratory (Liège University, CHU, Liège, Belgium)

The Georges Debled’s androgens’ pool study reflects the daily production of androgens: